Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib

Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakano, Akiko, Ohkubo, Hirotsugu, Fukumitsu, Kensuke, Fukuda, Satoshi, Kanemitsu, Yoshihiro, Takemura, Masaya, Maeno, Ken, Ito, Yutaka, Oguri, Tetsuya, Niimi, Akio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522408/
https://www.ncbi.nlm.nih.gov/pubmed/30568147
http://dx.doi.org/10.2169/internalmedicine.1890-18
Descripción
Sumario:Nintedanib has been shown to significantly reduce the annual rate of decline in the forced vital capacity (FVC) in patients with idiopathic pulmonary fibrosis (IPF) in previous randomized trials. A 71-year-old man developed exertional dyspnea and was diagnosed with IPF. Four months after treatment with nintedanib, high-resolution computed tomography findings revealed reduced areas of ground-glass opacity and consolidation; 13 months after treatment, the FVC showed improvement from 3.07 to 3.43 L, and the serum Krebs von den Lungen (KL)-6 concentration showed a decline to normal levels. We herein report a patient with IPF who was considered a super responder to nintedanib.

Ejemplares similares